SEARCH:   Advanced

Blood, 2 July 2009, Vol. 114, No. 1, pp. 148-152. Prepublished online as a Blood First Edition Paper on April 27, 2009; DOI 10.1182/blood-2008-11-187724. This Article Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-11-187724v1 114/1/148    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Santamaria, C. M. Articles by Gonzalez, M. Search for Related Content PubMed PubMed Citation Articles by Santamaria, C. M. Articles by Gonzalez, M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 5, 2008 Accepted March 25, 2009 Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia (CN-AML) Carlos M. Santamaria, Maria C. Chillon, Ramon Garcia-Sanz*, Cristina Perez, Maria D. Caballero, Fernando Ramos, Alfonso Garcia de Coca, Jose M. Alonso, Pilar Giraldo, Teresa Bernal, Jose A. Queizan, Juan N. Rodriguez, Pascual Fernandez-Abellan, Abelardo Barez, Maria J. Penarrubia, Ana Balanzategui, Maria B. Vidriales, Maria E. Sarasquete, Miguel Alcoceba, Joaquin Diaz-Mediavilla, Jesus F. San Miguel, and Marcos Gonzalez Hospital Universitario, Salamanca, Spain Centro de Investigacion del Cancer-IBMCC (USAL-CSIC) of Salamanca, Salamanca, Spain Hospital Clinico San Carlos, Madrid, Spain Complejo Hospitalario de Leon, Leon, Spain Hospital Clinico de Valladolid, Valladolid, Spain Hospital Rio Carrion de Palencia, Palencia, Spain Hospital Miguel Servet, Zaragoza, Spain Hospital Central de Asturias, Oviedo, Spain Hospital General de Segovia, Segovia, Spain Hospital Juan Ramon Jimenez, Huelva, Spain Hospital Universitario de Alicante, Alicante, Spain Hospital Nuestra Senora de Sonsoles, Avila, Spain Hospital Rio Hortega, Valladolid, Spain * Corresponding author; email: rgarcias{at}usal.es. We have evaluated nine new molecular markers (ERG, EVI1, MLL-PTD, MN1, PRAME, RHAMM, and WT1 gene expression levels plus FLT3 and NPM1 mutations) in 121 de-novo cytogenetically normal acute myeloblastic leukemias (CN-AML). In the multivariate analysis, high ERG or EVI1 and low PRAME expressions were associated with shorter relapse free and overall survival (RFS & OS). A 0 to 3 score was given by assigning a value of 0 to favorable parameters (low ERG, low EVI1 and high PRAME) and 1 to adverse parameters. This model distinguished four subsets of patients with different OS (2-yr OS of 79%, 65%, 46% and 27%; p=0.001) and RFS (2-yr RFS of 92%, 65%, 49% and 43%; p=0.005). Furthermore, this score identified patients with different OS (p=0.001) and RFS (p=0.013) even within the FLT3/NPM1 intermediate/high-risk subgroups. Here we propose a new molecular score for CN-AML which could improve patient risk-stratification. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: V. G. Oehler, K. A. Guthrie, C. L. Cummings, K. Sabo, B. L. Wood, T. Gooley, T. Yang, M. T. Epping, Y. Shou, E. Pogosova-Agadjanyan, et al. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells Blood, October 8, 2009; 114(15): 3299 - 3308. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020